Search clinical trials for: Combine Mirabegron and Solifenacin.

Total 2713 results

Astellas Pharma Europe Ltd.

Completed

A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)

Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Overactive

United States, Armenia, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Greece, Hungary, Ireland, Israel, Italy, Lebanon, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slov... and more
Astellas Pharma Europe B.V.

Completed

A Study to Compare How Much Solifenacin Succinate and Mirabegron Reach the Blood When Administered Together as Fixed-dose Combination Tablets and With Single Individual Tablets of the Same Medications at Three Dose Levels

Healthy Subjects | Bioavailability | Phase 1

Germany
Genuine Research Center, Egypt
Hikma Pharma

Completed

Bioequivalence Study of Solifenacin Succinate & Mirabegron From Mirfenacin MR 5/50 mg Extended Release Tablets (Hikma Pharma, Egypt) Versus Vesicare 5 mg FCT & Betmiga 50 mg Prolonged-Release Tablets (Astellas Pharma Europe B.V, the Netherlands / Astellas Pharma Europe B.V, the Netherlands)

Healthy

Egypt
Chang Gung Memorial Hospital

Unknown

Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

Overactive Bladder Syndrome | Detrusor Overactivity
Ono Pharmaceutical Co. Ltd

Completed

Study of ONO-8577 in Patients With Overactive Bladder

Overactive Bladder

Japan
Astellas Pharma Inc

Completed

A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously

Healthy Volunteers | Pharmacokinetics of Mirabegron

France
Mansoura University

Recruiting

Mirabegron, Propevirine, Solifenacin for Treatment of Lower Urinary Tract Symptoms During Intravesical BCG Instillation

Voiding Disorders

Egypt
National Taiwan University Hospital

Completed

Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes

Overactive Bladder Syndrome

Taiwan
Astellas Pharma Europe B.V.

Completed

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (SYNERGY)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

United States, Argentina, Australia, Belgium, Bulgaria, Canada, China, Colombia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico, Netherlands and more
Mackay Memorial Hospital

Recruiting

Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity

Urinary Bladder, Overactive | Effect of Drug | Urodynamics

Taiwan
Far Eastern Memorial Hospital

Recruiting

Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Overactive Bladder Syndrome

Taiwan
Astellas Pharma Inc

Completed

A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients

Overactive Bladder

Japan
Buddhist Tzu Chi General Hospital

Unknown

Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP

Overactive Bladder Syndrome

Taiwan
Bangabandhu Sheikh Mujib Medical University, Dhaka...

Completed

Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

Overactive Bladder

Bangladesh
Astellas Pharma Europe B.V.

Completed

A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (SYNERGY II)

Overactive Bladder | Urgency Incontinence | Urinary Bladder Overactive | Urinary Bladder Diseases\Urologic Diseases

Belgium, Russian Federation, Korea, Republic of, United States, Germany, Spain, Australia, Bulgaria, Canada, Czechia, Denmark, Estonia, Finland, Hungary, Italy, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, ... and more
The Affiliated Ganzhou Hospital of Nanchang University

Active, not recruiting

Acupuncture Combined With Mirabegron in the Treatment of OAB (ACWMITTOOAB)

Overactive Bladder

China
China Medical University Hospital

Recruiting

Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

Sjogren's Syndrome | Overactive Bladder Syndrome

Taiwan
Mansoura University

Recruiting

Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

Ureteral Stent | Stent Related Symptoms

Egypt
Far Eastern Memorial Hospital

Recruiting

Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin

Overactive Bladder Syndrome

Taiwan
Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects

Healthy Subjects | Pharmacokinetics | Drug-Drug Interaction (DDI)

Germany
Astellas Pharma Inc

Completed

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

Overactive Bladder (OAB)

Japan
Astellas Pharma Singapore Pte. Ltd.

Completed

Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania

Overactive Bladder (OAB)

Korea, Republic of, Australia
Astellas Pharma Europe B.V.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (Symphony)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases | Urological Manifestations | Signs and Symptoms

Belarus, Belgium, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Romania, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Tamsulosin Hydrochloride (HCl) Concentrations in Blood in Healthy Male Subjects

Healthy Subjects | Pharmacokinetics | Drug-Drug Interaction (DDI)

Germany
Astellas Pharma Europe Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment. (BEYOND)

Urologic Diseases | Urinary Bladder, Overactive | Urinary Bladder Diseases

Greece, Ireland, Armenia, Austria, Belarus, Belgium, Bulgaria, Canada, Czechia, Denmark, Finland, France, Georgia, Germany, Hungary, Italy, Kazakhstan, Latvia, Lebanon, Lithuania, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovaki... and more
Astellas Pharma Singapore Pte. Ltd.

Completed

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

Overactive Bladder (OAB)

Korea, Republic of, Taiwan
Astellas Pharma Europe B.V.

Completed

A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)

Pediatric | Neurogenic Detrusor Overactivity

United States, Belgium, Korea, Republic of, Philippines, Poland, United Kingdom
Astellas Pharma Europe Ltd.

Completed

Vesitirim™ in Men Postmarketing Observational Study (VIM)

Overactive Bladder (OAB) | Lower Urinary Tract Symptoms (LUTS)

Ireland
Mansoura University
Ahmed Mohamed Elshal

Completed

Efficacy of Li-SWT on Persistent Storage Symptoms After Transurethral Surgery for BPO

Overactive Bladder | Urinary Incontinence, Urge | Urgency-frequency Syndrome | Post Prostatectomy

Egypt
Astellas Pharma Inc

Completed

Relative Bioavailability Study of Solifenacin Succinate Liquid Suspension (Fed and Fasting) Versus VESIcare Tablet (Fasting) in Healthy Volunteers

Healthy Volunteers | Pharmacokinetics of Solifenacin Succinate | Bioavailability of Solifenacin Succinate

United States
Hanmi Pharmaceutical Company Limited

Completed

Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers

Overactive Bladder
Astellas Pharma Inc

Completed

Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents

Urinary Bladder, Overactive

Sweden, United Kingdom, Belgium, Denmark
Astellas Pharma Europe B.V.

Completed

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076 (LEOPARD)

Urinary Bladder, Overactive

Belgium, United States, Brazil, Canada, Denmark, Former Serbia and Montenegro, Korea, Republic of, Mexico, Norway, Philippines, Poland, South Africa, Sweden, Turkey, Ukraine, United Kingdom
Center Eugene Marquis

Terminated

Solifenacin Succinate for Treatment of Urinary Toxicity Occurring During Radiotherapy of Prostatic Cancer (VesiCaP)

Overactive Bladder

France
Xing Liu

Recruiting

Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children

Overactive Bladder | Urinary Bladder, Overactive | Urinary Incontinence, Urge

China
Lahey Clinic
Astellas Pharma US, Inc.

Terminated

Behavioral Modification and Vesicare Versus Vesicare Alone for Urge Incontinence in Patients With Overactive Bladder

Overactive Bladder

United States
Astellas Pharma Inc

Completed

A Study to Evaluate Absorption, Distribution and Elimination of Mirabegron After Oral Administration to Non-elderly Healthy Chinese Subjects

Healthy Subjects | Plasma Concentration of Mirabegron

Japan
National Taiwan University Hospital

Unknown

Comparisons of 3-month Versus 6-month Solifenacin Treatment for Female OAB Patients

Overactive Bladder Syndrome

Taiwan
Astellas Pharma Inc

Completed

A Study in Healthy Volunteers Comparing Two Different Liquid Formulations of Solifenacin With Each Other and With the Tablet Formulation

Healthy Volunteers | Pharmacokinetics of Solifenacin Succinate

United States
Thomas Jefferson University
Astellas Pharma Inc

Terminated

Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot Study

Achalasia

United States
Astellas Pharma Inc

Completed

A Study to Find Out How Much Mirabegron Gets Into the Body After Dosing With a Tablet Formulation

Healthy Subjects | Bioavailability | Pharmacokinetics of Mirabegron

Netherlands
KYU-SUNG LEE
Astellas Pharma Korea, Inc.

Completed

A Study to Evaluate Add on Effect of Solifenacin in Men With Overactive Bladder Symptoms After Tamsulosin Monotherapy for 4 Weeks

Overactive Bladder

Korea, Republic of
Loyola University
Astellas Pharma US, Inc.

Completed

Bacterial Genomic Sequencing in Overactive Bladder

Overactive Bladder

United States
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

A Study to Evaluate Response of Over Active Bladder Symptom Score to Solifenacin Treatment (RESORT-2)

Over Active Bladder

Korea, Republic of
Seattle Urology Research Center

Unknown

Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)

Nocturia | Urinary Urgency | Urinary Frequency

United States
Baylor Research Institute
The Methodist Hospital Research Institute; International Urogynecological Association

Completed

Higher Neural Changes Following Anticholinergic, Beta 3 Agonist, or Placebo in Patients With Overactive Bladder

Overactive Bladder | Lower Urinary Tract Symptoms | Dementia | Incontinence, Urge

United States
Elsayed Abdelhalim Elsayed

Completed

Management of OAB in Female Patients .

Overactive Bladder

Egypt
Loyola University
Astellas Pharma US, Inc.

Completed

Incontinence & Intimate Partners: Assessing the Contribution of Treatment (IIMPACT)

Urge Urinary Incontinence

United States
Cedars-Sinai Medical Center

Recruiting

Using Mirabegron to Increase BP in Patients With POTS (RAISE BP)

Syncope | Postural Orthostatic Tachycardia Syndrome | Chronic Orthostatic Intolerance

United States
Far Eastern Memorial Hospital

Recruiting

Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing

Overactive Bladder Syndrome

Taiwan

Search clinical trials for: Combine Mirabegron and Solifenacin.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations